{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:36:31Z","timestamp":1774251391561,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Health Serv."],"abstract":"\n Objective<\/jats:title>\n The escalating incidence of prostate cancer poses a significant global public health challenge. Optimal utilization of resources is crucial for the effective deployment of funds among the diverse and emerging treatment options for managing prostate cancer. This systematic review aims to offer insights and serve as a reference for pharmacoeconomic studies related to the use of degarelix and luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of prostate cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a comprehensive search in databases including Embase, PubMed, the Cochrane Library, CNKI, Web of Science, Scopus, and the Tufts CEA Registry to identify cost-effectiveness studies on the use of degarelix and LHRH agonists in the treatment of prostate cancer, spanning from the inception of these databases up to December 30, 2025. Two independent reviewers sequentially examined titles, abstracts, and full-text articles, applying predefined inclusion and exclusion criteria to select studies for data extraction. Any disagreements were resolved through discussion until a consensus was reached. The quality of the included studies was evaluated using the Quality of Health Economic Studies and Consolidated Health Economic Evaluation Reporting Standards. Relevant data were then summarized and comparatively analyzed, focusing on aspects such as the model framework, model parameters, and uncertainty analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 13 studies were ultimately incorporated, with an overall high quality but significant methodological variations among them. Five studies compared degarelix with leuprorelin, goserelin, or triptorelin; four compared triptorelin to goserelin or leuprorelin; one study evaluated leuprorelin acetate in a 6-month depot formulation vs. a 3-month depot; two compared leuprorelin to goserelin and triptorelin; and one study assessed radiotherapy vs. radiotherapy plus goserelin. Eight studies employed the Markov model, with time horizons spanning from 1 year to 30 years. The majority of the studies (\n n<\/jats:italic>\n \u2009=\u20097) conducted cost-effectiveness analyses, and most were based in developed countries (\n n<\/jats:italic>\n \u2009=\u20097). Degarelix was deemed cost-effective in the United States, United Kingdom, and China. Additionally, 6-month depot LHRH agonists were found to be more cost-effective than their monthly or 3-monthly counterparts.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n From a societal perspective, the evidence suggests that degarelix may be a cost-effective option for patients with prostate cancer. All assessments of LHRH agonists are of high quality. Among the three LHRH agonists evaluated, the 6-month depot formulation of triptorelin may be a cost-effective option in certain settings. In clinical practice, the evaluation of a drug should comprehensively consider its efficacy, adverse effects, cost-effectiveness, and overall patient survival. The evidence is predominantly derived from high-income countries, and thus the conclusions may have limited generalizability to low- and middle-income country settings.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/recorddashboard<\/jats:ext-link>\n , PROSPERO CRD420250653923.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/frhs.2026.1608532","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:42:35Z","timestamp":1774248155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review"],"prefix":"10.3389","volume":"6","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Hebei Medical University Third Hospital","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"You","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hebei Medical University Third Hospital","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hebei Medical University Third Hospital","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hebei Medical University Third Hospital","place":["Shijiazhuang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12957-025-03937-5","article-title":"Global, regional, and national burden and trends of prostate cancer in elderly from 1990 to 2021: results from global burden of disease 2021","volume":"23","author":"Li","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1002\/cncr.34905","article-title":"The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance","volume":"129","author":"Horn\u00fd","year":"2023","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.prnil.2025.06.001","article-title":"Burden of prostate cancer in China during 1990\u20132021 and the projections through 2050","volume":"13","author":"Hua","year":"2025","journal-title":"Prostate Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"942800","DOI":"10.3389\/fpubh.2022.942800","article-title":"Degarelix vs. Leuprorelin for the treatment of prostate cancer in China: a cost-utility analysis","volume":"10","author":"Yan","year":"2022","journal-title":"Front Public Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.13286\/j.1001-5213.2022.16.18","article-title":"Economic evaluation of triptorelin in the treatment of locally advanced or metastatic prostate cancer in China","volume":"42","author":"Tang","year":"2022","journal-title":"Chin J Hosp Pharm"},{"key":"B8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.19546\/j.issn.1674-3830.2019.2.014","article-title":"A cost-utility analysis of degarelix in the treatment of prostate cancer in China","volume":"2","author":"Xuan","year":"2019","journal-title":"China Health Insur"},{"key":"B9","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Br Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"Br Med J"},{"key":"B11","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.clinthera.2022.01.011","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"44","author":"Husereau","year":"2022","journal-title":"Clin Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/13696998.2017.1362410","article-title":"Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6- month and 3-month depot formulations","volume":"20","author":"Goto","year":"2017","journal-title":"J Med Econ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1586\/erp.13.13","article-title":"Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer","volume":"13","author":"Hatoum","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jval.2010.10.023","article-title":"Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy","volume":"14","author":"Iannazzo","year":"2011","journal-title":"Value Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3111\/13696998.2014.893240","article-title":"A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom","volume":"17","author":"Lee","year":"2014","journal-title":"J Med Econ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1464-410X.2011.10434.x","article-title":"Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer","volume":"109","author":"Lu","year":"2012","journal-title":"BJU Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/s0959-8049(01)00197-6","article-title":"Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis","volume":"37","author":"Neymark","year":"2001","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/CEOR.S485856","article-title":"Resources utilization assessment and cost-minimization analysis of the 6-monthly formulation of triptorelin in the treatment of prostate cancer in China","volume":"16","author":"Chen","year":"2024","journal-title":"Clinicoecon Outcomes Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100982","DOI":"10.1016\/j.vhri.2024.01.004","article-title":"Cost-Effectiveness analysis of triptorelin, goserelin, and leuprolide in the treatment of patients with metastatic prostate cancer: a societal perspective","volume":"42","author":"Rezaee","year":"2024","journal-title":"Value Health Reg Issues"},{"key":"B21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/13696998.2023.2172281","article-title":"Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England","volume":"26","author":"Cornford","year":"2023","journal-title":"J Med Econ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5505\/tjo.2020.2449","article-title":"Cost-effectiveness analysis of leuprorelin acetate atrigel in the treatment of prostate cancer","volume":"35","author":"\u00d6zyi\u011fit","year":"2020","journal-title":"Turk Onkoloji Dergisi"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.13263\/j.cnki.nja.2013.12.015","article-title":"Androgen deprivation therapy for prostate cancer: a follow-up study of the patients\u2019 survival time","volume":"19","author":"Zhang","year":"2013","journal-title":"Zhong hua Nan Ke Xue"}],"container-title":["Frontiers in Health Services"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2026.1608532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:42:39Z","timestamp":1774248159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2026.1608532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":23,"alternative-id":["10.3389\/frhs.2026.1608532"],"URL":"https:\/\/doi.org\/10.3389\/frhs.2026.1608532","relation":{},"ISSN":["2813-0146"],"issn-type":[{"value":"2813-0146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1608532"}}